EP 0 729 758 A3

(12)

EUROPEAN PATENT APPLICATION

- (88) Date of publication A3: 29.10.1997 Bulletin 1997/44
- (51) Int Cl.6: A61K 31/505

(11)

- (43) Date of publication A2: 04.09.1996 Bulletin 1996/36
- (21) Application number: 96300931.1
- (22) Date of filing: 12.02.1996
- (84) Designated Contracting States:

 AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT
 SE
- (30) Priority: 02.03.1995 US 397527
- (71) Applicant: PFIZER INC. New York, N.Y. 10017 (US)

- (72) Inventor: Yuhpyng, Chen L. Waterford, Connecticut 06385 (US)
- (74) Representative: Hayles, James Richard et al Pfizer Limited, Patents Department, Ramsgate Road Sandwich Kent CT13 9NJ (GB)
- (54) Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders.
- (57) Pyrazolopyrimidines and pyrrolopyrimidines of the general formula

wherein A, X, R³, R⁴ and R⁵ are defined in the application, and pharmaceutically acceptable salts of such compounds, are useful in the treatment or prevention of certain neuronal and other disorders.

EP 0 729 758 A3

Printed by Jouve, 75001 PARIS (FR)

Applicants: Arlindo Castelhano et al. Serial No.: 10/718,280

Filed: November 20, 2003 Exhibit 7



EUROPEAN SEARCH REPORT

Application Number EP 96 30 0931

<u>_</u>	DOCUMENTS CONSI			
Category	Citation of document with indication, where appropriate, of relevant passages		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CL6)
D,X	WO 94 13677 A (PF1Z (US)) 23 June 1994 * claims 1-12 *	ER ;CHEN YUHPYNG LIANG	1-16	A61K31/505
D,X	WO 94 13676 A (PFIZ (US)) 23 June 1994 * claims 1-12 *	ER ;CHEN YUHPYNG L	1-16	
P,X	WO 95 10506 A (DU P April 1995 * page 1-4 * * table 10 * * claims 1-10 *	ONT MERCK PHARMA) 20	1-16	
P, Y	WO 95 33750 A (PFIZ (US)) 14 December 1 * claims 1-22 *		1-16	
Y	US 4 213 977 A (CRE July 1980 * column 2, line 8	ANGE JOHN E ET AL) 22 - line 21 *	1-15	TECHNICAL FIELDS SEARCHED (Int.Cl.4)
D,X	DE 31 45 287 A (TRO 19 May 1983 * page 10, line 19-	PONWERKE GMBH & CO KG) 21; claims 1-10 *	1-15	A61K
D,X	1992	SIA PHARMA) 29 July line 38; claims 1-27 *	1-15	
х	WO 94 13643 A (PFIZER ; FARACI WILLIAM STEPHEN (US); WELCH WILLARD MCKOWAN JR (US)) 23 June 1994 * claims 1-10 *		1-16	
Р,Х	EP 0 691 128 A (PFI * claims 1-6 * compounds (C) VIII,	ZER) 10 January 1996 (D) I	1-15	
		-/		
	The present search report has b			
Place of search Date of completing of the search				F.x amuner
	MUNICH	19 August 1997	See	egert, K
CATEGORY OF CITED DOCUMENTS T: theory or princip E: earlier patent de X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background C: non-written disclosure B: intermediate document			cument, but pub ate in the application or other reasons	olished on, ur

2



European Patent Office

С	LAIMS INCURRING FEES
The pre	sent European patent application comprised at the time of filling more than ten claims
	All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
	Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid,
	namely claims:
	No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.
L	ACK OF UNITY OF INVENTION
	arch Division considers that the present European patent application does not comply with the requirement of invention and relates to several inventions or groups of inventions, namely:
	See sheet -8-
×	All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
□ .	Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.
	namely claims:
	None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims,
•	namely claims:



EUROPEAN SEARCH REPORT

Application Number EP 96 30 0931

ategory	Citation of document with it of relevant pa	dication, where appropriate, sages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IncCt6)
Ο,Υ	US 5 063 245 A (ABR November 1991 * column 5, line 1	·	1-16	
D,Y	EP 0 005 205 A (TROPONWERKE GMBH & CO KG) 14 November 1979 * page 7, line 26 - page 8, line 5 * * claims 1-10 *		1-15	
Y	PHARM. REV., vol. 43, 1991, pages 425-473, XP00 OWENS M.J. ET AL: Pharmacology of Cor factor" * page 447 * "B. Metabolic Respo Corticotropin-relea Administration" * page 457 - page 4 sections IX and X	"Physiology and ticotropin-releasing nses to sing Factor	1-16	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Y	inhibits neuronal d	94, 2038091 T AL: asing factor antagonis amage induced by focal or activation of NMDA	1-15 t	SEARCHED (III-C.)
	The present search report has t	·		
	Place of search	Date of complains of the search		Exagniner
	MUNICH	19 August 1997	Se	egert, K
X:pai Y:pai do: A:tec	CATEGORY OF CITED DOCUME rticularly relevant if taken alone rticularly relevant if combined with an cument of the same category hnological background a written disclosure	E : earlier patent of after the filiage other D : document circle.	focument, but put date I in the application I for other reason	blished on, or on s

PO FORM



LACK OF UNITY OF INVENTION SHEET B

Application Number

ANNRY

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

- The subject-matter of the present application relates to the use of compounds of formula (I) for the manufacture of a medicament for the prevention/treatment of numerous disorders as claimed in Claim 1.
- The common concept linking the different therapeutic applications as claimed resides in the fact that the compounds exhibit corticotropin-releasing factor (CRF) antagonist activity (see e.g. page 1, lines 18 26 of the description).
- 3. However, this common concept is already known from the prior art (see e.g. WO-A-9413677 or WO-A-9413676, also cited on pages 2 3 of the description). Consequently, the therapeutic applications as claimed in the present application are no longer linked by a common concept. Thus the requirements of Article 82 EPC are not mer
- 4. The following different inventions have been identified:

Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing or inhibiting a disorder selected from

- head trauma, spinal cord trauma (partly Claims 1 -15)
- ischemic neuronal damage, excitotoxic damage (partly Claims 1 - 15)
- epilepsy (partly Claims 1 15)
- 4. stroke (partly Claims 1 15)
- 5. stress induced immune dysfunctions (partly Claims 1- 15, Claim 16)
- 6. phobias (partly Claims 1 15)



LACK OF UNITY OF INVENTION SHEET B

Application Number

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

- muscular spasms (partly Claims 1 15)
- 8. Parkinson's disease (partly Claims 1 15)
- 9. Huntington's disease (partly Claims 1 15)
- 10. urinary incontinence (partly Claims 1 15)
- 11. senile dementia of the Alzheimer's type (partly
 Claims 1 15)
- 12. multiinfarct dementia (partly Claims 1 15)
- 13. amyotrophic lateral sclerosis (partly Claims 1 15)
- 14. chemical dependencies and addictions (partly Claims
 1 15)
- 15. hypoglycemia (partly Claims 1 15)
- For the time being the search has been restricted to the first subject-matter.



EUROPEAN SEARCH REPORT

Application Number EP 96 30 0931

	DOCUMENTS CONSID			
Category	Citation of document with inc of relevant pass		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	BRAIN RES. (NETHERLA vol. 545, no. 1-2, 1 pages 339-342, XP002 LYONS M.K. ET AL: " releasing factor ant ischemic hippocampal abstract *	991, 038092 Corticotropin agonist reduces	1-15	
Υ	AM. J. PHYSIOL. (UNITED STATES), vol. 255, no. 3 PT 1, 1988, pages 287-292, XP002038093 WIDMAIER E.P. ET AL: "Regulation of corticotropin-releasing factor secretion in vitro by glucose" * abstract * * page 291, last paragraph - page 292 *		1-15	
Y	ANN. PHARMACOTHER. (UNITED STATES), vol. 28, no. 6, 1994, pages 779-791, XP002038094 HAINES S.T. ET AL: "Treatment of infantile spasms" * page 781, right-hand column *		1-15	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Y	CLINICAL NEUROPHARMACOLOGY, vol. 9, no. 2, 1986, pages 202-205, XP002038095 KLAWANS H.L. ET AL: "Myoclonus and Parkinsonism" * abstract *		1-15	
	The present search report has he			
Place of search Date of completion of the search			•	F.x.attudet
	MUNICH	19 August 1997	7 See	egert, K
X: particularly relevant if taken alone after the Y: particularly relevant if combined with another D: documen document of the same category L: document A: technological background			rinciple underlying the int document, but pub- ling date aired in the application ited for other reasons the same patent family	lished on, or

7